We demonstrated that the composition and quantity of cell types found within therapeutic BM-MNC preparations for use in clinical trials of cardiac stem cell transplantation are not influenced by the type of density gradient media used when comparing Ficoll-Paque and Lymphoprep.
This study compared CD34 selection procedures using the CellPro CEPRATE and the Baxter Isolex 300 systems. Thirty-two procedures were performed, 19 CEPRATE and 13 Isolex. Median starting CD34 percentages were (CEPRATE/Isolex) 0.80% (range 0.24%-7.73%) and 0.85% (range 0.27%-10.17%), respectively (p = 0.788). After selection, there was a highly significant difference in purity of the product (CEPRATE/Isolex), 54% and 82% respectively (p < 0.0001). There was no significant difference in median recovery (CEPRATE/Isolex), 43% and 50%, respectively (p = 0.383). The starting CD34 percentage influenced the purity of the final product, and at high and low starting percentages, the Isolex produced superior purity. Improved efficacy of T cell depletion was observed with the Isolex, a median log depletion of 3.4 compared with 2.9 for the CEPRATE system (p = 0.012). In conclusion, the Isolex 300i produced a significantly higher purity CD34+ fraction, even at starting CD34+ levels of <0.5%, with no significant difference in recovery when compared with the CEPRATE system. The associated log T cell depletion is significantly improved with the Isolex system, with possible implications for use in CD34-selected allogeneic transplants.
Summary:Allogeneic SCT for myeloma may be curative for young patients, but its role remains controversial because of a reported high TRM in some series. Since 1991, we have performed 25 allografts for myeloma using fully matched sibling donors. Of the 18 evaluable patients, 13 achieved CR at a median time of 2.5 months post-transplant. The five patients who were not in CR when assessed at 3 months received a short course of a-interferon and four subsequently achieved CR with this approach at a median of 82 days. One patient who failed to respond to IFN went on to achieve CR after four doses of DLI therapy, thus giving an overall CR rate of 72%. Seven patients have relapsed at a median of 4.7 years post-transplant (range 1.38-7.7 years) including two patients who had received IFN therapy. In five of these cases, relapse has been as a localised area of bone disease or isolated plasmacytoma with no evidence of marrow involvement by trephine biopsy or molecular analysis. All patients with localised relapse were treated with local radiotherapy 7DLI and four are currently disease free despite two patients having had further treatment for a second localised lesion. Six patients died of TRM (24%) and the OS at 8 years is currently 69% with an EFS of 26%. These results suggest that allogeneic SCT for myeloma can be carried out with an acceptable TRM and a high CR rate. However, late relapses as localised disease may be a frequent finding and may represent foci of myeloma not eradicated by the conditioning. The use of pretransplant MRI scanning and top-up radiotherapy to involved areas may be useful in preventing this type of relapse. Allogeneic transplantation for multiple myeloma has been shown to result in a high CR rate and is thought to be curative for a proportion of individuals. 1 However, conventional allografts for myeloma have remained controversial owing to the high reported TRM rates which has led to superior survival being demonstrated for patients undergoing autologous transplants compared to allografts. 2 Although recent data suggest that there has been a major improvement in survival of conventional myeloma allografts since 1994 owing to a significant reduction in transplant-related mortality, 3 many centres are instead exploring the use of nonmyeloablative allogeneic transplants for patients with myeloma. In principle, this should be associated with a low transplant-related mortality, relying on the potent graft-versus-myeloma effect to elicit a cure. However, the relapse risk of this approach is still unknown. Indeed, relapse remains a major concern even after conventional allografts for myeloma, where it is estimated to be 45% at 5 years 1 and with no apparent plateau in the relapse rate being seen on the most recent EBMT registry analysis. 3 In our series of 25 patients receiving conventional myeloablative-matched sibling allografts for myeloma, we have observed seven cases of relapsed disease. In five of these cases relapse occurred late, as an isolated osteolytic lesion or solitary plasmacytoma witho...
Objectives: Biosimilar filgrastim was compared with lenograstim for autologous haematopoietic stem-cell transplant (HSCT) in patients with haematological malignancies. Data from a separate group of sibling donors who underwent allogeneic HSCT are also reported. Methods: Patients with lymphoma or multiple myeloma (MM) who underwent autologous HSCT with biosimilar filgrastim were compared with a historical control group of patients who received lenograstim. Peripheral blood (PB) cells counts were monitored after 7-8 consecutive days of granulocyte-colony stimulating factor (G-CSF) injection and apheresis was performed on day 8 if PB CD34+ cell count was ⩾10 cells/µl. The target PB CD34+ cell doses were ⩾2.0 × 10 6 /kg (lymphoma), ⩾4.0 × 10 6 /kg (MM ⩾60 years old) or ⩾8.0 × 10 6 /kg (MM <60 years old). Results: A total of 259 patients were included in the autologous HSCT comparison (biosimilar filgrastim, n = 104; lenograstim, n = 155). In patients with lymphoma and older MM patients (⩾60 years old), no significant differences were observed between groups with regard to stem-cell mobilization parameters. However, in MM patients <60 years old, all parameters were significantly superior in the biosimilar filgrastim group, including the need for 1 rather than 2 apheresis procedures. No significant differences were observed between groups in median number of days to absolute neutrophil count (ANC) or platelet recovery. In the allogeneic setting, 47 sibling donors received biosimilar filgrastim. Mean CD34+ count at the first apheresis was 6.1 × 10 6 /kg. A total of 13 donors needed a second apheresis and 4 required a third. Among recipients, median days to ANC recovery was 16 (10-28) and to platelet recovery was 13 (9-54). Conclusions: Biosimilar filgrastim is as effective as lenograstim for autologous HSCT in patients with lymphoma or MM patients ⩾60 years old. However, mobilization with biosimilar filgrastim appeared to be superior to that with lenograstim in younger MM patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.